Standout Papers
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC (2018)
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial (2008)
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial (2019)
- Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial (2012)
- Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced Myelosuppression (1988)
- Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial (2015)
- Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial (2020)
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial (2015)
- Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial (2016)
- IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC (2021)
- Cardiac Toxicity After Radiotherapy for Stage III Non–Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy (2017)
- Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial (2020)
- Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer (2023)
Immediate Impact
5 by Nobel laureates 5 from Science/Nature 137 standout
Citing Papers
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Lung cancer
2021 Standout
Works of Mark A. Socinski being referenced
Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.
2020
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
2020 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Mark A. Socinski | 14798 | 15354 | 4880 | 516 | 22.4k | |
| Chandra P. Belani | 13911 | 13125 | 6250 | 454 | 21.6k | |
| Corey J. Langer | 16729 | 17063 | 5718 | 556 | 27.9k | |
| Solange Peters | 17096 | 18833 | 5876 | 421 | 29.1k | |
| Suresh S. Ramalingam | 14115 | 15160 | 8642 | 584 | 24.7k | |
| David R. Gandara | 18069 | 16654 | 7907 | 641 | 29.1k | |
| Byoung Chul Cho | 12497 | 12760 | 5501 | 672 | 19.0k | |
| Nagahiro Saijo | 13140 | 16116 | 9018 | 551 | 25.0k | |
| Harry J.M. Groen | 11993 | 8633 | 4739 | 547 | 19.7k | |
| D. Ross Camidge | 16480 | 14715 | 8384 | 533 | 23.6k | |
| Jacek Jassem | 7771 | 11155 | 4695 | 510 | 19.3k |
All Works
Login with ORCID to disown or claim papers
Loading papers...